Type 2 diabetes with good glycemic control have improved insulin response and lower non-esterified fatty acid level after a meal challenge

Norhayati Yahaya, Win Mar Kyi, Norhayati Mohd Noor, Wan Mohamed Wan Bebakar

.
Endocrine Unit, Department of Medicine, Universiti Sains Malaysia, Penang, Malaysia.

DOI: 10.4236/jdm.2012.21001                

Abstract

Background: Pathogenesis of type 2 diabetes (T2DM) involves defects in β-cell function with impaired first and second phase insulin response, and reduced insulin sensitivity. Diabetic dyslipidemia is an important and common risk factor for coronary heart disease (CHD). Aims: This study examined the effect of glycemic control on post prandial insulin and lipid parameters in response to a standardised meal challenge among Type 2 diabetes patients with good and poor glycemic control. Methods: We cross-sectionally studied 31 T2DM patients with good glycemic control and 32 T2DM patients with poor glycemic control. Subjects were given, after minimum 10 hours of fasting, a standard meal containing 58% fat. Fasting and serial postprandial blood samples were taken over 8 hours to determine levels of triglyceride, direct LDL-C, apoB lipoprotein, non-esterified-fatty-acid, insulin and blood glucose. Results: Post prandial NEFA was significantly higher in poor controlled diabetes patients compared to good control diabetes patients (p = 0.019), and post-hoc analysis showed significant difference from 3 hours post prandial to 4 hours post prandial, where p= 0.021. Although the difference in insulin between the 2 groups did not reach statistical significance (p =0.058), post-hoc analysis showed significant difference between the 2 groups from fasting to 1 hour post prandial (p = 0.034) despite postprandial glucose being significantly higher in poor controlled diabetes patients (p < 0.001), throughout the postprandial period. Conclusion: T2DM patients with good glycemic control have improved insulin response with lower non-esterified fatty acid.

Keywords

Insulin Response; Non-Esterified Fatty Acid; Standardised Meal; Type 2 Diabetes; Glycemic Control

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Taskinen, M.R. (2003) Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia, 46, 733-749. doi:10.1007/s00125-003-1111-y
[2]	Lowe, L.P., Liu, K., Greenland, P. et al. (1997) Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: The Chicago heart association detection project in industry study. Diabetes Care, 20, 163-169. doi:10.2337/diacare.20.2.163
[3]	The DECODE Study Group, the European Diabetes Epidemiology Group. (1999) Glucose tolerance and mortality: Comparison of WHO and ADA diagnostic criteria. Lancet, 354, 617-621. doi:10.1016/S0140-6736(98)12131-1
[4]	Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A. and Laakso, M. (2003) The STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. Journal of the American Medical Association (JAMA), 290, 486-494. doi:10.1001/jama.290.4.486
[5]	Bansal, S., Buring, J.E., Rifai, N., Mora, S., Sacks, F.M. and Ridker, P.M. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Journal of the American Medical Association (JAMA), 298, 309-316. doi:10.1001/jama.298.3.309
[6]	Nordestgaard, B.G., Benn, M., Schnohr, P. and Tybjaerg-Hansen, A. (2007) Nonfasting triglycerides and risk of myocardial infarction, ischaemic heart disease, and death in men and women. Journal of the American Medical Association (JAMA), 298, 299-308. doi:10.1001/jama.298.3.299
[7]	Phillips, C., Murugasu, G., Owens, D., Collins, P., Johnson, A. and Tomkin, G.H. (2000) Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis, 148, 283-291. doi:10.1016/S0021-9150(99)00275-0
[8]	Turner, R.C., Cull, C.A., Frighi, V. and Holman, R.R. (1999) Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association (JAMA), 281, 2005-2012. doi:10.1001/jama.281.21.2005
[9]	Matthews, D.R., Cull, R.A., Stratton, I.M., Holman, R.R. and Turner, R.C. (1998) UKPDS 26: Sulfonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Medicine, 15, 297-303. doi:10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N
[10]	Robertson, P.R., Harmon, J., Tran, O.P., Tanaka, Y. and Takahashi, H. (2003) Glucose Toxicity in β-cell: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection. Diabetes, 52, 581-587. doi:10.2337/diabetes.52.3.581
[11]	Tiege, M., Lortz, S., Munday, R. and Lenzen, S. (1998) Complementary action of antioxidant enzymes in the protention of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes, 47, 1578-1585. doi:10.2337/diabetes.47.10.1578
[12]	Rivellese, A.A., De Nalate, C., Di Marino, L., Patti, L., Iovine, C., Coppola, S., et al. (2004) Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. Journal of Clinical Endocrinology and Metabolism, 89, 2153-2159. doi:10.1210/jc.2003-031764
[13]	Valabhji, J. and Elkeles, R.S. (2003) Dyslipidemia in Type 2 Diabetes: Epidemiology and Biochemistry. The British Journal of Diabetes and Vascular Disease, 3, 184-189.
[14]	Zhou, Y.P. and Grill, V. (1995) Long term exposure to fatty acids and ketones inhibits B-cell function in human pancreatic islets of Langerhans. Journal of Clinical Endocrinology and Metabolism, 80, 1584-1590. doi:10.1210/jc.80.5.1584
[15]	Briaud, I., Harmon, J.S., Kelpe, C.L., Segu, V.B. and Poitout, V. (2001) Lipotoxicity of the pancreatic B-cell is associated with gliucose—Dependent esterification of fatty acids into neutral lipids. Diabetes, 50, 315-321. doi:10.2337/diabetes.50.2.315
[16]	Maedler, K., Spinas, G.A., Dyntar, D., Moritz, W., Kaiser, N. and Donath, M.Y. (2000) Distincts effects of saturated and monosaturated fatty acids on b-cell turnover and function. Diabetes, 50, 69-76. doi:10.2337/diabetes.50.1.69
[17]	Kahn, S.E. (2001) The Importance of β-cell failure in the development and progression of type 2 diabetes: Clinical review. Journal of Clinical Endocrinology and Metabolism, 86, 4047-4058. doi:10.1210/jc.86.9.4047